Cipla Q1 net dips 39% to ₹785.55 crore as North America business drags
Cipla reported a 39% decline in net profit for the first quarter, falling to ₹785.55 crore due to weak performance in the North American market. Despite the overall dip, the company saw revenue growth in India and maintained steady performance in other international markets.
Why it matters
The results highlight the volatility of the pharmaceutical sector and the impact of regional market dependencies on corporate earnings.
Drugmaker Cipla’s consolidated net profit for the quarter ended June declined 39% to ₹785.55 crore compared to the ₹1,291.61 crore in the corresponding period last year on the back of lower sales in the key North America market.
The net profit came on a more than 2% increase in total revenue from operations to ₹7,119.28 crore (₹6,957.47 crore).
Contributing to the revenue growth was a 12% increase in India business to ₹3,452 crore (₹3,070 crore). The U.S. business posted a revenue of ₹1,532 crore (₹1,933 crore). “We expect continued sequential growth in North America, supported by upcoming product pipeline,” MD and Global CEO Achin Gupta said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in